Literature DB >> 2017198

Biodegradable microspheres as a vaccine delivery system.

J H Eldridge1, J K Staas, J A Meulbroek, J R McGhee, T R Tice, R M Gilley.   

Abstract

The utility of biodegradable and biocompatible microspheres as a vaccine delivery system for the induction of systemic and disseminated mucosal antibody responses was investigated. Intraperitoneal (ip) injection into mice of 1-10 microns microspheres, constructed of the copolymer poly(DL-lactide-coglycolide) (DL-PLG) which contained approximately 1% by weight a formalinized toxoid vaccine of staphylococcal enterotoxin B (SEB), dramatically potentiated the circulating IgG anti-toxin antibody response as compared to the free toxoid. The initiation of vaccine release was delayed in larger microspheres, and a mixture of 1-10 and 20-50 microns microspheres stimulated both a primary and an anamnestic secondary anti-toxin response following a single injection. However, neither free nor microencapsulated SEB toxoid induced a detectable mucosal IgA anti-toxin response following systemic injection. In contrast, three peroral immunizations with toxoid-microspheres stimulated circulating IgM, IgG and IgA anti-toxin antibodies and a concurrent mucosal IgA response in saliva, gut washings and lung washings. Systemic immunization with microencapsulated toxoid primed for the induction of disseminated mucosal IgA responses by subsequent oral or intratracheal (it) boosting in microspheres, while soluble toxoid was ineffective at boosting. These results indicate that biodegradable and biocompatible microspheres represent an adjuvant system with potentially widespread application in the induction of both circulating and mucosal immunity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2017198     DOI: 10.1016/0161-5890(91)90076-v

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  40 in total

1.  Cross-linked protein crystals for vaccine delivery.

Authors:  N St Clair; B Shenoy; L D Jacob; A L Margolin
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity.

Authors:  C Sedlik; G Dadaglio; M F Saron; E Deriaud; M Rojas; S I Casal; C Leclerc
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

3.  Single-dose mucosal immunization with biodegradable microparticles containing a Schistosoma mansoni antigen.

Authors:  B Baras; M A Benoit; L Dupré; O Poulain-Godefroy; A M Schacht; A Capron; J Gillard; G Riveau
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

4.  Collagen type II and a thermo-responsive polymer of N-isopropylacrylamide induce arthritis independent of Toll-like receptors: a strong influence by major histocompatibility complex class II and Ncf1 genes.

Authors:  Akhilesh Kumar Shakya; Ashok Kumar; Dorota Klaczkowska; Malin Hultqvist; Kristin Hagenow; Rikard Holmdahl; Kutty Selva Nandakumar
Journal:  Am J Pathol       Date:  2011-09-18       Impact factor: 4.307

Review 5.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

6.  Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen.

Authors:  S J Challacombe; D Rahman; H Jeffery; S S Davis; D T O'Hagan
Journal:  Immunology       Date:  1992-05       Impact factor: 7.397

7.  Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres.

Authors:  K Allaoui-Attarki; S Pecquet; E Fattal; S Trollé; E Chachaty; P Couvreur; A Andremont
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

Review 8.  Influenza vaccines. A reappraisal of their use.

Authors:  A M Palache
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

9.  Targeting to intestinal M cells.

Authors:  M A Jepson; M A Clark; N Foster; C M Mason; M K Bennett; N L Simmons; B H Hirst
Journal:  J Anat       Date:  1996-12       Impact factor: 2.610

10.  Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics.

Authors:  Jacob William Coffey; Gaurav Das Gaiha; Giovanni Traverso
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-08-31       Impact factor: 13.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.